APO-SALVENT STERULES SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
16-03-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
SALBUTAMOL (SALBUTAMOL SULFATE)
Tillgänglig från:
APOTEX INC
ATC-kod:
R03AC02
INN (International namn):
SALBUTAMOL
Dos:
0.5MG
Läkemedelsform:
SOLUTION
Sammansättning:
SALBUTAMOL (SALBUTAMOL SULFATE) 0.5MG
Administreringssätt:
INHALATION
Enheter i paketet:
2.5 ML
Receptbelagda typ:
Prescription
Terapiområde:
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0108887009; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2001-05-11
Produktens egenskaper
_Page 1 of 32_
PRODUCT MONOGRAPH
PR
APO-SALVENT RESPIRATOR SOLUTIONS
(SALBUTAMOL SULFATE SOLUTIONS BP)
PR
APO-SALVENT RESPIRATOR SOLUTION 50 MG IN 10 ML (5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 1.25 MG IN 2.5 ML (0.5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 2.5 MG IN 2.5 ML (1 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 5.0 MG IN 2.5 ML (2 MG/ML SALBUTAMOL)
BRONCHODILATOR,
Β
2
-ADRENERGIC STIMULANT
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
March 16, 2020
CONTROL # 236795
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................................................
8
DOSAGE AND ADMINISTRATION
........................................................................................................................
10
OVERDOSAGE
..........................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
Läs hela dokumentet
